The company projects plozasiran to generate $2 billion to $3 billion annually in the SHTG market alone, with Phase III studies (SHASTA-3, SHASTA-4, and MUIR 3) expected to complete enrollment this ...

During the recent period, Arrowhead (ARWR) signed and closed a potentially transformational licensing and collaboration agreement with Sarepta ...

The Lipodystrophy market growth is driven by factors like increase in the prevalence of Lipodystrophy, investments in research and development, entry of emerging therapies during the study period 2020 ...

Certain foods have generated devoted followings among people from all walks of life. While flavorful foods can be hard to ...

Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

The global cholesterol and lipid test market value is anticipated to expand from USD 3.0 billion in 2024 to USD 6.2 billion by 2034. Over the assessment period, demand for cholesterol and lipid test ...

Shares of 89bio (NASDAQ:ETNB) were up 40% Monday afternoon, stoked by positive data for Akero Therapeutics' (NASDAQ:AKRO) drug efruxifermin in the treatment of compensated liver cirrhosis due to MASH.

Plozasiran sodium (AROAPOC-3) is under development for the treatment of severe hypertriglyceridemia, mixed dyslipidemia and familial Chylomicronemia. It is administered through the subcutaneous route.

This is not one but a group of risk factors for heart disease, stroke, and diabetes. Many ways that hypertriglyceridemia is treated are also the same measures used to prevent it. High triglyceride ...

The utility of left atrial appendage occlusion (LAAO) as a therapy for stroke prevention in patients with nonvalvular atrial fibrillation (AFib) is the focus of a State-of-the-Art Review published Jan ...

SAN FRANCISCO--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation ...

Work, practice, expense and liability relative value units (RVUs) are updated annually through the Centers for Medicare and Medicaid Services' Medicare Physician Fee Schedule (PFS) rulemaking. In ...